問卷

TPIDB > Search Result

Search Result

篩選

List

22Cases

2023-09-01 - 2027-04-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2024-01-01 - 2030-11-30

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2029-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2025-03-31 - 2028-05-06

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2025-09-24 - 2028-11-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2030-12-24

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-11-07 - 2029-09-25

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-03-08 - 2027-06-15

Phase I

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-12-15 - 2028-06-29

Phase I/II

Not yet recruiting
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    輸注液

Participate Sites
4Sites

Recruiting4Sites

1 2 3